Table 2.

Characteristics of rheumatoid arthritis patients at disease onset, grouped by occurrence of cardiovascular disease (CVD) event and all-cause mortality during followup.

All,Incident CVD EventAll-cause Mortality
n = 741Yes, n = 177No, n = 564Died, n = 151Survived, n = 590
Age, years55.0 ± 14.765.9 ± 11.8***51.5 ± 13.867.5 ± 11.4***51.8 ± 13.7
Females, %67.555.9***71.157.0**70.2
Smoking ever vs never, %58.759.958.368.9**56.1
Hypertension, %16.731.6***12.128.5***13.7
Diabetes mellitus, %5.19.3**3.89.5**3.9
Hyperlipidemia, %0.81.70.52.00.5
RF positivity, %59.562.958.367.6*57.3
ACPA positivity, %55.553.356.25655.4
CRP, mg/l19 (6–46)23 (10–54)**17 (6–43)27 (12–59)***17 (6–42)
ESR, mm/h36 ± 2638 ± 2535 ± 2741 ± 26**34 ± 26
WBC8.2 ± 2.68.7 ± 2.7**8.1 ± 2.68.9 ± 2.9***8.0 ± 2.5
DAS285.1 ± 1.35.1 ± 1.35.1 ± 1.35.2 ± 1.45.1 ± 1.2
HAQ0.99 ± 0.621.0 ± 0.670.98 ± 0.601.09 ± 0.70*0.96 ± 0.59
VAS pain, mm45.3 ± 24.145.0 ± 25.545.4 ± 23.643.8 ± 26.445.7 ± 23.4
DMARD, start, %84.175.7***86.780.884.9
MTX, start, %43.739.644.842.643.9
GC, start %51.455.950.057.649.8
  • Values are mean ± SD or medians (IQR) depending on values distribution. P values for between-group differences:

  • * p < 0.05;

  • ** p ≤ 0.01;

  • *** p ≤ 0.001. CVD: cardiovascular disease; RF: rheumatoid factor; ACPA: anticitrullinated peptide antibody; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; WBC: white blood (cell) count; DAS28: Disease Activity Score in 28 joints; HAQ: Health Assessment Questionnaire; VAS pain: visual analog scale for pain; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate; GC: glucocorticoids.